»
«
QR Code QR Code
Post Offer Free
Shanghai Yijing Pharmaceutical&Chemical Co.,Ltd
Shanghai Yijing Pharmaceutical&Chemical Co.,Ltd

China China Supplys High Quality SARMS MK-1775 Powder manufacturer

2nd

Gold Index: 126398

You are here: home  > New Raw SARM Powder  > China Supplys High Quality SARMS MK-1775 Powder

China Supplys High Quality SARMS MK-1775 Powder 

Price: 50.0 USD 
Payment Terms: T/T,WU,Money Gram;Bitcoin 
Place of Origin: Shanghai, China (Mainland) 
inquire skype
Add to My Favorites
HiSupplier Escrow
Share |

Product Detail

Model No.: 955365-80-7
Production Capacity: 50kg/month
Delivery Date: Within 24 hours
CAS No.: 955365-80-7
Molecular formula: C27H32N8O2
Grade: Pharmaceutical Grade
Storage: Shading, confined preservat...
Shipment: EMS, DHL, FedEx, TNT
Leading Time: About 5~8 working days
Means of Transport: Ocean,Land,Air
Packing: Discreet Package
Brand Name: Yijing
Purity: 99%
Molecular weight: 500.6
Appearance: White Powder
Payment Terms: Wester Union,Money Gram,Ban...
Certification: GMP, HSE, ISO 9001, USP, BP
Delivery Time: Within 24 hours

MK-1775 Bodybuilding Supplement
MK-1775 Ovarian Cancer
MK-1775 Muscle Growth
MK-1775 SARM Powder
MK-1775 Tumor Inhibition

Skype: histeroids

Whatsapp:+86 18121080540


MK-1775 CAS:955365-80-7

FW: 500.61

Formula: C27H32N8O2

Purity: 99%


Description: 

MK-1775, also known as adavosertib, AZD-1775, is a WEE1 inhibitor, is also a small molecule inhibitor of the tyrosine kinase WEE1 with potential antineoplastic sensitizing activity. MK-1775 selectively targets and inhibits WEE1, a tyrosine kinase that phosphorylates cyclin-dependent kinase 1 (CDC2) to inactivate the CDC2/cyclin B complex. Inhibition of WEE1 activity prevents the phosphorylation of CDC2 and impairs the G2 DNA damage checkpoint. This may lead to apoptosis upon treatment with DNA damaging chemotherapeutic agents.Doctors usually treat ovarian cancer with surgery. You may also have chemotherapy. Paclitaxel and carboplatin are 2 of the chemotherapy product that doctors often use to treat ovarian cancer.


Unfortunately, ovarian cancer can come back after surgery and chemotherapy. If this happens, you may have more chemotherapy. But researchers are looking for ways to improve treatment for ovarian cancer that has come back. In this trial, they are looking at a drug called MK-1775 alongside chemotherapy.MK-1775 is a type of biological therapy.  It is a cancer growth blocker. It stops signals that cancer cells use to divide and grow.


Detail Informations:

This compound inhibits phosphorylation of CDC2 at Tyr15 (CDC2Y15), a direct substrate of Wee1 kinase in cells. MK-1775 abrogates G(2) DNA damage checkpoint, leading to apoptosis in combination with DNA-damaging chemotherapeutic agents such as gemcitabine, carboplatin, and cisplatin selectively in p53-deficient cells. In vivo, MK-1775 potentiates tumor growth inhibition by these agents, and cotreatment does not significantly increase toxicity. The enhancement of antitumor effect by MK-1775 was well correlated with inhibition of CDC2Y15 phosphorylation in tumor tissue and skin hair follicles. Our data indicate that Wee1 inhibition provides a new approach for treatment of multiple human malignancies.


MK-1775, a potent Wee1 inhibitor, synergizes with gemcitabine to achieve tumor regressions, selectively in p53-deficient pancreatic cancerMK-1775 treatment led to the inhibition of Wee1 kinase and reduced inhibitory phosphorylation of its substrate Cdc2. MK-1775, when dosed with GEM, abrogated the checkpoint arrest to promote mitotic entry and facilitated tumor cell death as compared to control and GEM-treated tumors. MK-1775 monotherapy did not induce tumor regressions. However, the combination of GEM with MK-1775 produced robust antitumor activity and remarkably enhanced tumor regression response (4.01-fold) compared to GEM treatment in p53-deficient tumors. Tumor regrowth curves plotted after the drug treatment period suggest that the effect of the combination therapy is longer-lasting than that of GEM. None of the agents produced tumor regressions in p53 wild-type xenografts. 


Biological Activity

MK-1775 is a potent and selective inhibitor of the tyrosine kinase WEE1 (IC50 = 5.2 nM). It selectively targets and inhibits WEE1, a tyrosine kinase that phosphorylates cyclin-dependent kinase 1 (CDC2) to inactivate the CDC2/cyclin B complex. Inhibition of WEE1 activity prevents the phosphorylation of CDC2 and impairs the G2 DNA damage checkpoint. This may lead to apoptosis upon treatment with DNA damaging chemotherapeutic agents. 

Ms. Leslie@pharm-china.com
skype Ms. Leslie@pharm-china.com
Sales Manager
Tel: 86-181-21080540
Fax: 86-181-21080540
Mobile: 86- 181 2108 0540
Contact to this supplier

Didn't find what you're looking for? Post Buying Lead or contact HiSupplier Customer Service Center  for help!

Related Search

Find more related products in following catalogs on Hisupplier.com

Other products from this supplier

Company Info

Shanghai Yijing Pharmaceutical&Chemical Co.,Ltd [China (Mainland)]


Business Type:Manufacturer
City: Shanghai
Province/State: Shanghai
Country/Region: China (Mainland)

Follow Us: Follow us on linkedin Follow us on Twitter

Ms.Leslie:   skype

You May Like: